Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Defends Imaging, Backs Comparative Effectiveness At Hearing

This article was originally published in The Gray Sheet

Executive Summary

Device industry representatives defended advanced imaging use and supported use of carefully defined clinical comparative effectiveness research during a House committee hearing on health care reform June 24
Advertisement

Related Content

Groups Emphasize Long-Term Focus On Comparative Effectiveness Research
Groups Emphasize Long-Term Focus On Comparative Effectiveness Research
White House Again Looks To Imaging Cuts To Help Raise Health Reform Funds
White House Again Looks To Imaging Cuts To Help Raise Health Reform Funds
Republicans Set Up Roadblocks For Comparative Effectiveness Provisions
Dueling Comparative Effectiveness Provisions Outlined In Senate Reform Bills
MedPAC Study Finds Self-Referring Doctors Drive Up Imaging Use, Costs
Physicians Get Temporary Reprieve Under CMS Plan To Phase In Imaging Cuts

Topics

Advertisement
UsernamePublicRestriction

Register

MT027599

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel